Communiqués Avacta Group Plc

Actions

AVCT

GB00BYYW9G87

Recherche biotechnologique et médicale

Marché Fermé - London S.E. 08:30:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
72,00 ^GBX	-.--%		-0,69%	+24,14%

05/10	Avacta lève des fonds ; Orcadian met fin à son accord de développement	AN
30/09	Avacta Group Plc publie ses résultats pour le semestre clos le 30 juin 2026	CI

Communiqués

30/09	Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update	GL
30/09	Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update	AQ
25/09	Avacta Group plc: The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer	GL
16/09	Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre\|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial	GL
16/09	Avacta : Research & Development Spotlight Series – Episode 16	PU
16/09	Avacta : Achieves Clinical Proof of Mechanism for the Next Generation of pre\|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial	PU
14/09	Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee	GL
23/07	Avacta : Research & Development Spotlight Series – Episode 15	PU
21/07	Avacta : Academy – Episode 4	PU
09/07	Avacta : Accelerated Amortized Payment of Convertible Bond Installment	PU
08/07	Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors	GL
25/06	Avacta : Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer	PU
01/06	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	GL
01/06	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	AQ
29/05	Avacta : Annual Report and Accounts for the year ending 31 December 2025	PU
19/05	Unaudited Preliminary Results for the Year Ended December 31, 2025	GL
06/05	Avacta : presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	PU
06/05	Avacta presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	GL
21/04	Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre\|CISION® delivery platform	GL
14/04	Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders	GL
08/04	Avacta : Announces 2026 Science Day Event	PU
31/03	Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre\|CISION® exatecan peptide drug conjugate	GL
27/03	Avacta : Results of Oversubscribed Placing and Subscription	PU
26/03	Avacta : Proposed Placing via an accelerated bookbuild and Subscription to raise approximately £10 million	PU
17/03	Avacta Announces Preclinical and Translational Presentations of pre\|CISION® Platform Candidates at the 2026 AACR Annual Conference	GL